CLINICAL_TRIALS trial_result · 2022-02-08

Clinical Trial Update: An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness [Phase 3]

Phase 3 trial update on ARGX-113 for generalized myasthenia gravis reports completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2022-02-08